Sun Pharma’s focus on specialty drugs pays off

November 2, 2023

The company’s revenues grew 11% driven by strong growth posted by the India business and the global specialty sales in the US. A third of the company’s revenues is earned each from India and the US. Sun’s market share in India increased from 8.3% to 8.4% for the year ended September 2023.

More To Explore

ETMarkets Smart Talk: Diwali 2024 outlook! Vikas Gupta on why banking and power sectors are poised for growth in Samvat 2081

There could be other reasons due to the middle east war escalation with potential to cause spike in crude oil prices and also potentially creating

October 22, 2024

DIIs, not FIIs, are the real culprits of market pullback: Anurag Singh

Why should they buy? I mean, if everybody has to make their own judgment on what are they buying, what is their duration and what

October 22, 2024

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003